The application for the listing of Ravidawe, a hepatitis C innovative drug, was accepted by the State Drug Administration
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the, Theof the LimitedCompany (Co., Inc.), announced that its second new hepatitis C(Ravidasvir, RDV) as the future pan-genotype direct antiviraldrug(DAA) was included in the latest july 2018 version of the World Health Organization's guidelines for hepatitis C treatmentAugust 1st, the application for the listing of the new drug in Galway Ravidawe was accepted by the StateDrug(Supervisory Authority)about The RavidaweRavidawe is a new generation of pan-genotype NS5A inhibitors developed by Goliath, and has completed three Phase III clinical studies at home and abroad to date, with more than 1,000 subjects in the groupChina Phase II/III ClinicalTrial(results show that China's first primary oral hepatitis C cure, consisting of Ravidawe United Gonovir® (Danorivir, DNV), has a 12-week cure rate of 99% (SVR12) and is not affected by baseline NS5A resistance
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
